Non-invasive IGFBP1, IGFBP2 biomarkers as predictors and outcomes of usual interstitial pneumonia (UIP) therapeutic response

Abstract Background Usual interstitial pneumonia (UIP) is a fatal disease that associated with poor prognosis and survival. Several growth factors such as IGFs (insulin-like factors) IGFBPs factor binding proteins) seem to take part this pathogenesis. Pirfenidone an immunosuppressant drug thought have anti-inflammatory anti-fibrotic effects both in vitro vivo. Objective To assess IGFBP1 IGFBP2 non-invasive biomarkers for prediction outcomes of UIP clinical activity therapeutic response the pirfenidone. Results Serum levels were significantly higher group than healthy subjects ( p ≤ 0.005). After 6 months therapy, patients divided into 2 groups according improvement MRC dyspnea grading clinically improved non-improved groups. 6MWT SPaO2 compared one no differences regards other parameters < 0.0001). Both decreased serum while only was BAL all after completing 12 therapy. Conclusion increased active reduced anti-fibrosing may be promising predictors therapy UIP.